Tryptophan hydroxylase 1 expression is increased in phenotype-altered canine and human degenerative myxomatous mitral valves

Journal of Heart Valve Disease

Volumn 19, Issue 1, 2010, Pages 71-78

  Disatian, Sirilak ^a,b   Lacerda, Carla ^a   Christopher Orton, E ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; MYOSIN; NON MUSCLE EMBRYONIC MYOSIN; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG; ACTIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE MYXOMATOUS MITRAL VALVE DISEASE; DOG; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE MICROSCOPY; MITRAL VALVE DISEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; AGED; ANIMAL; AUTOCRINE EFFECT; CELL COUNT; FEMALE; IMAGE PROCESSING; MALE; METABOLISM; MIDDLE AGED; MITRAL VALVE; PATHOLOGY; PHYSIOLOGY;

ACTINS; AGED; ANIMALS; AUTOCRINE COMMUNICATION; CELL COUNT; DOGS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MITRAL VALVE; MYOSINS; SEROTONIN; TRYPTOPHAN HYDROXYLASE;

EID: 77950906118     PISSN: 09668519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with upregulation of low density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006;47:1707-1712
2. Freed L, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral valve prolapse. N Engl J Med 1999;341:1-7 (Pubitemid 29293713)
3. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001;104:2522-2532
4. Disatian S, Ehrhart EJ, Zimmerman S, Orton EC. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation. J Heart Valve Dis 2008;17:402-412
5. Rajamannan NM, Caplice N, Anthikad F, et al. Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects. J Heart Valve Dis 2001;10:827-831 (Pubitemid 33133581)
6. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995;92:790-795
7. Connally HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588 (Pubitemid 27360757)
8. Prichett A, Morrison J, Edwards W, Schaff H, Connally H. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286 (Pubitemid 35403801)
9. Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 2007;28:2156-2162 (Pubitemid 47517444)
10. Gustafsson BI, Tommeras K, Nordrum I, et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005;111:1517-1522 (Pubitemid 40470647)
11. Droogmans S, Roosens B, Cosyns B, et al. Dosedependency of serotonin on the heart valves in rats assessed by echocardiography. Eur Heart J 2008;29:649 (abstract supplement)
12. Jian B, Xu J, Savani R, Narula N, Liang B, Levy RJ. Serotonin mechanisms in heart valve disease I: Serotonin-induced upregulation of TGF-β1 via G-protein signal transduction in aortic valve interstitial cells. Am J Pathol 2002;161:2207-2216
13. Walker GA, Masters KS, Shah DN, Anseth KS, Leinvvand LA. Valvular myofibroblast activation by transforming growth factor β: Implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res 2004;95:253-260 (Pubitemid 39056285)
14. Walther DJ, Peter JU, Bashammakh S, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003;299:76 (Pubitemid 36042402)
15. Brouns I, Nassauw LV, Genechten JV, et al. Triple immunofluorescence staining with antibodies raised in the same species to study the complex innervations pattern of intrapulmonary chemoreceptors. J Histochem Cytochem 2002;50:575-582 (Pubitemid 34250597)
16. Negoescu, A, Labat-Moleur F, Lorimier P. F (ab) secondary antibodies: A general method for double immunolabeling with primary antisera from the same species. Efficiency control by chemiluminescence. J Histochem Cytochem 1994;43:433-437 (Pubitemid 24064489)
17. Walther DJ, Bader MA. A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 2003;66:1673-1680 (Pubitemid 37249312)
18. White KJ, Walline CC, Barker EL. Serotonin transporters: Implications for antidepressant drug development. AAPS J 2005;7:E421-E433
19. Ni W, Watts SW. 5-Hydroxytryptamine in the cardiovascular system: Focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 2006;33:575-583 (Pubitemid 43894017)
20. Rippe J, Fishbein MC, Carabello B, et al. Primary myxomatous degeneration of cardiac valves: Clinical, pathological, hemodynamic and echocardiographic profile. Br Heart J 1980;44:621-629 (Pubitemid 11213482)
21. Perderson HD, Häggström J. Mitral valve prolapse in the dog: A model of mitral valve prolapse in man. Cardiovasc Res 2000;47:234-243 (Pubitemid 30625286)
22. Disatian S, Orton CE. Autocrine serotonin and transforming growth factor β1 signaling mediates spontaneous myxomatous mitral valve disease. J Heart Valve Dis 2009;18:44-51